Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»281310.69541/NRIPH.2024.04.017Научная статьяIssues of organizing medicine provision for children who received treatment with the help of the “Circle of kindness” foundation upon their reach of majorityKomarovIlya A.iliya_komarov@mail.ruhttps://orcid.org/0000-0002-1518-184XGevorkyanAnait K.GevorkyanAK@rmapo.ruhttps://orcid.org/0000-0002-2731-1349N. A. Semashko National Research Institute of Public HealthFGBOU DPO RMANPE of the Ministry of Health of Russia27112024411011507052025Copyright © 2025,2025<p>In 2021, in the Russian Federation, by Decree of the President of the Russian Federation, the Circle of Good Fund was created to support children aged 0 to 18 years with severe life-threatening and chronic diseases, including rare (orphan) diseases. According to the Program of State Guarantees for the free provision of medical care to citizens, financial support is provided from federal budget allocations in accordance with the procedure for purchasing medicines and medical products for a specific child with a serious life-threatening or chronic disease, including a rare (orphan) disease, or for groups of such children established by the Government of the Russian Federation. Noting the absolute feasibility of creating the Fund, it is necessary to raise the issue of organizing drug provision for children who received treatment with the help of the Circle of Good Foundation when they reach adulthood. This article analyzes the existing approaches to this organization, and also presents possible proposals aimed at improving this process.</p>rare diseasesorphan drugschildrenCircle of Good Foundationdrug supplyhealthcareState Guarantee Programредкие болезниорфанные лекарственные препаратыдетифонд «Круг добра»лекарственное обеспечениездравоохранениеПрограмма государственных гарантий1.Komarov I.A., Sokolov А.А., Aleksandrova O.Yu. Issues of high-technology medical service providing for patients with orphan diseases. Health care Standardization Problems. [Problemy standartizacii v zdravoohranenii]. 2019;(7—8):63—72 (in Russian). DOI: 10.26347/1607-2502201907-08063-0722.3.Komarov I.A., Aleksandrova O.Yu., Nagibin O.A. Current organization of drug maintenance for certain patient groups. Role of drug lists. Healthcare Manager. [Menedzher zdravoohraneniya].2019;(5):53—60 (in Russian).4.5.Komarov I.A., Malakhova A.R., Vasilyeva T.P. et al. Socioeconomic efficiency of neonatal screening for spinal muscular atrophy in the Russian Federation. Neuromuscular Diseases. [Nervno-myshechnye bolezni]. 2023;13(3):25—32 (in Russian). DOI: 10.17650/2222-8721-2023-13-3-25-326.7.Kulikov A.Yu., Komarov I.A. Pharmacoeconomic analysis of the drug Beyodaime (pertuzumab + trastuzumab [set]) in the treatment of metastatic breast cancer in patients with the HER2+ form of the disease. Pharmacoeconomics: Theory and Practice. [Farmakoekonomika: teoriya i praktika]. 2015;3(2):32—9 (in Russian).8.9.Kulikov A.Yu., Komarov I.A. Pharmacoeconomic study of the use of bronchodilators of the M-anticholinergic group (Spiriva® and Atrovent®) in the treatment of chronic obstructive pulmonary disease. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. [Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya]. 2012;(3):20—6 (in Russian).